Product Images Levetiracetam

This is a description of a medication called Levetiracetam in 0.82% Sodium Chloride solution for intravenous infusion. Each 100 mL contains 500 mg of levetiracetam, 820 mg of sodium chloride, and other components. The usual dosage should be checked as per the package insert. The medication should be infused over 15 minutes and should not be further diluted before use. The storage conditions recommended are between 20°C to 25°C (68°F to 77°F) with excursions allowed between 15°C to 30°C (59°F to 86°F). The container is a single-dose dual port container and does not contain natural rubber latex, PVC, or DEHP.*

This text provides detailed information about a medication called Levetiracetam in 0.75% Sodium Chloride Injection, which is intended for intravenous infusion only. Each 100mL contains 1,000mg of levetiracetam. It should be infused over a period of 15 minutes and not be further diluted before use. The medication should be stored between 20°C to 25°C (68°F to 77°F) with excursions permitted between 15°C to 30°C (59°F to 86°F). The container closure is specified to not include natural rubber latex, PVC, or DEHP. Additionally, it mentions not to use plastic containers in series connections. The text also provides a cautionary note, dosage instructions, and information about discarding any unused portion.*

This text provides detailed information about Levetiracetam in 0.54% Sodium Chloride injection, including dosage, storage recommendations, and handling instructions. It specifies the composition per 100mL, caution regarding plastic containers, and the single-dose dual port container features. It is manufactured by B. Braun Medical Inc. in Bethlehem, USA. The barcode is printed at the time of production.*

This is a detailed description of a pharmaceutical product called Levetiracetam, supplied in a 100 mL PAB® container. The solution contains 500 mg of Levetiracetam in 0.82% Sodium Chloride for intravenous infusion. Each milliliter of the solution contains 5 mg of Levetiracetam. The recommended infusion duration is over a period of 15 minutes. The container should not be diluted further before use, and caution is advised against using plastic containers for connections. The storage temperature recommendation is between 20°C to 25°C. The container closure is not made with natural rubber latex, PVC, or DEHP. The product is meant for single-dose use and is Rx only. The provided text includes information about the composition, storage, and precautions for using the medication.*

This is a description of Levetiracetam injection in a 100 mL PAB® container with 10 mg/mL concentration. It is intended for intravenous infusion only over a 15-minute period. The solution contains 1000 mg of Levetiracetam, water, sodium chloride, glacial acetic acid, and sodium acetate. The recommended storage temperature is between 20°C to 25°C. The container closure does not contain natural rubber latex, PVC, or DEHP. It warns against using plastic containers in series connections and advises against further dilution before use.*

This is a description of a medication product containing Levetiracetam in 0.54% Sodium Chloride solution for intravenous infusion. Each 100 mL contains 1,500 mg of Levetiracetam. It is recommended to infuse over 15 minutes and to store the product between 20°C to 25°C. The package is a single-dose container and the closure is not made with natural rubber latex, PVC, or DEHP. It is advised not to use plastic containers for connections, and the product should not be further diluted before use. It is essential to refer to the package insert for the usual dosage. This product is for prescription use only.*

This is the second step of process illustrated in Figure C. It involves peeling off towards the additive.*

This text provides data on the percentage of participants in a study receiving different doses of Levetiracetam compared to placebo. The results indicate that Levetiracetam at 1000 mg/day and 3000 mg/day showed statistically significant effects compared to placebo. The sample size for each group is also provided.*

This is a table showing the percentage of results for different groups in a study comparing a placebo group with two groups taking different dosages of levetiracetam. The data presented includes the percentage of results for each group, with a note stating that one of the levetiracetam groups had statistically significant results compared to the placebo group. The study had a total of 111 participants in the placebo group, 106 participants in the 1000 mg/day levetiracetam group, and 105 participants in the 2000 mg/day levetiracetam group.*

This text appears to show the percentage of patients in a study comparing a placebo group with a group receiving Levetiracetam at a dosage of 3000 mg/day. It mentions that the Levetiracetam group had statistically significant results compared to the placebo group. The sample size for the placebo group was 104, while the sample size for the Levetiracetam group was 180.*

This text appears to contain statistical percentages of patients in a study comparing a placebo group (N=84) and a racetam group (N=79). The results indicate that the racetam group showed a statistically significant difference compared to the placebo group.*